(Q50130669)

25 February 2018

title

Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. (English)

1 reference

25 February 2018

1 reference

1

1 reference

25 February 2018

author name string

Bjarke Ebert

series ordinal

2

1 reference

25 February 2018

Klaus Larsen

series ordinal

3

1 reference

25 February 2018

Brigitte Tonnoir

series ordinal

4

1 reference

25 February 2018

publication date

19 October 2011

1 reference

25 February 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

25 February 2018

volume

15

1 reference

25 February 2018

issue

6

1 reference

25 February 2018

page(s)

715-725

1 reference

25 February 2018

Which antidepressants have demonstrated superior efficacy? A review of the evidence

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Gaboxadol -- a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Escitalopram in the acute treatment of depressed patients aged 60 years or older

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Effective Dose of Escitalopram in ModerateversusSevere DSM-IV Major Depression

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The EEG effects of THIP (Gaboxadol) on sleep and waking are mediated by the GABA(A)delta-subunit-containing receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The GABAA agonist THIP (gaboxadol) increases non-REM sleep and enhances delta activity in the rat

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The effect of escitalopram on sleep problems in depressed patients

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Superiority of escitalopram to paroxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Escitalopram prevents relapse in older patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The onset of effect for escitalopram and its relevance for the clinical management of depression.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The measurement of disability.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100112X

7 January 2021

10.1017/S146114571100112X

Identifiers

DOI

1 reference

25 February 2018

1 reference

25 February 2018